Dali Pharmaceutical Co. Ltd. provided earnings guidance for the year 2018. According to preliminary statistics of its financial department, the Company predicts a decrease of between RMB 32.45 million and RMB 34.45 million in its net profit owned by shareholders of the listed company in 2018 compared with the same period of the year before, with a year-on-year decrease of between 73% and 78% (based on the disclosed statistics according to relevant regulations). The net profit belonging to shareholders of the listed company after excluding extraordinary profit and loss in 2018 will decrease by between RMB 34.01 million and RMB 34.81 million compared with the same period of the year before, with a year-on-year increase of between 92% and 94% (based on the disclosed statistics according to relevant regulations).